Sumitomo Pharma Co., Ltd. (DNPUF)

Sumitomo Pharma Balance Sheet

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Cash & Equivalents	20,453	23,116	29,047	143,478	202,984	193,698
Cash & Short-Term Investments	20,453	23,116	29,047	143,478	202,984	193,698
Cash Growth	-73.91%	-20.42%	-79.75%	-29.32%	4.79%	90.44%
Accounts Receivable	83,380	74,840	81,023	95,908	151,407	135,866
Other Receivables	2,751	2,886	16,216	2,722	93	194
Receivables	86,131	77,726	97,239	98,630	151,500	136,060
Inventory	89,751	94,222	115,350	94,405	99,021	92,215
Other Current Assets	60,383	58,104	27,933	45,347	46,016	37,822
Total Current Assets	256,718	253,168	269,569	381,860	499,521	459,795
Property, Plant & Equipment	46,103	46,648	57,895	58,909	64,091	64,966
Long-Term Investments	7,346	72,339	182,368	144,399	127,909	203,277
Goodwill	191,175	197,406	199,783	209,415	195,144	176,492
Other Intangible Assets	164,726	172,509	195,652	329,314	398,692	383,406
Long-Term Deferred Tax Assets	502	534	2,239	10,845	22,650	20,191
Other Long-Term Assets	66,763	-	-	-	-	-
Total Assets	733,333	742,604	907,506	1,134,742	1,308,007	1,308,127
Accounts Payable	39,308	38,544	67,720	52,141	46,183	64,638
Short-Term Debt	-	42,440	174,588	90,588	5,025	5,000
Current Portion of Long-Term Debt	50,188	4,000	110,929	-	20,060	4,960
Current Portion of Leases	-	3,354	3,781	4,660	5,463	5,900
Current Income Taxes Payable	1,002	1,577	1,348	24,053	7,583	24,511
Other Current Liabilities	141,189	147,224	157,108	199,446	194,059	173,138
Total Current Liabilities	231,687	237,139	515,474	370,888	278,373	278,147
Long-Term Debt	259,057	258,982	133,367	244,128	243,963	263,859
Long-Term Leases	-	5,470	5,199	6,996	10,033	10,961
Long-Term Deferred Tax Liabilities	25,892	26,550	38,211	36,505	26,550	28,424
Other Long-Term Liabilities	33,987	38,450	47,969	64,435	64,058	63,489
Total Liabilities	557,100	573,125	751,370	727,960	634,438	659,949
Common Stock	22,400	22,400	22,400	22,400	22,400	22,400
Additional Paid-In Capital	-	-	-	-	16,725	15,855
Retained Earnings	57,924	46,784	-22,665	280,999	514,210	508,677
Treasury Stock	-682	-682	-682	-682	-681	-679
Comprehensive Income & Other	96,591	100,977	157,010	104,032	55,234	34,317
Total Common Equity	176,233	169,479	156,063	406,749	607,888	580,570
Minority Interest	-	-	73	33	65,681	67,608
Shareholders' Equity	176,233	169,479	156,136	406,782	673,569	648,178
Total Liabilities & Equity	733,333	742,604	907,506	1,134,742	1,308,007	1,308,127
Total Debt	309,245	314,246	427,864	346,372	284,544	290,680
Net Cash (Debt)	-288,792	-291,130	-398,817	-202,894	-81,560	-96,982
Net Cash Per Share	-726.90	-732.79	-1003.84	-510.69	-205.29	-244.11
Filing Date Shares Outstanding	397.29	397.29	397.29	397.29	397.29	397.29
Total Common Shares Outstanding	397.29	397.29	397.29	397.29	397.29	397.29
Working Capital	25,031	16,029	-245,905	10,972	221,148	181,648
Book Value Per Share	443.59	426.59	392.82	1023.80	1530.08	1461.31
Tangible Book Value	-179,668	-200,436	-239,372	-131,980	14,052	20,672
Tangible Book Value Per Share	-452.23	-504.51	-602.51	-332.20	35.37	52.03

Updated Jan 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.